This review summarises the use of engineered ketoreductases (KREDS), both as whole microbial cells and isolated enzymes, in the highly enantiospecific reduction of prochiral ketones.
Automated high throughput workflow facilitating the rapid optimization and development of immobilized enzymes – ready to be scaled – and thus matching the need for speed in modern drug development.
An efficient, green, and stereoselective synthesis of cis-(2S,3S)-2,3-dihydro-3-hydroxy-2-aryl-1,5-benzothiazepin-4(5H)-ones was developed via ketoreductase-catalyzed dynamic reductive kinetic resolution.
An asymmetric sustainable route to D-pantothenic acid was developed, centering on the reduction of ethyl 2′-ketopantothenate to ethyl (R)-pantothenate, enabled by an E. coli strain co-expressing an engineered ketoreductase and glucose dehydrogenase.
WT ChKRED20 which exhibits no activity towards γ,δ-keto esters was redesigned for reducing bulky keto esters to the corresponding lactones.